Awards and Honors, Free News Articles, NonProfit and Charities, Regional Events

November Is C. difficile Awareness Month With An Annual Conference, Recognizing Subject Matter Experts, Expressing Gratitude to US Governors

TAMPA, Fla. -- C Diff Foundation announced today that the 9th Annual International C. diff. Conference and Health EXPO welcomed over 40 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, and academia on November 4-5, 2021. World-renowned presenters delivered data and discussed critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile with global healthcare-associated issues: 100% Live-online presentations.

The Conference registration was complimentary this year. To learn more about this extraordinary conference, guest speakers, and the diverse topics presented visit: https://www.cdiff2021.com

For conference coverage visit ContagionLive Infectious Diseases Today: https://www.contagionlive.com/latest-conference

On behalf of the C Diff Foundation, Sahil Khanna, M.B.B.S, M.S. proudly presented the Lifetime Achievement Award to Dale Gerding, MD, MACP, FIDSA, FSHEA for his outstanding vision, dedication, and commitment and for the advancement of Clostridioides difficile research, development, and care through the years. The Dale Gerding Lifetime Achievement award will be presented annually during the C Diff Foundation's November conference to a healthcare professional meeting the criteria, nominated by peers, and awarded by Dr. Gerding himself.

The C Diff Foundation "Making a Difference: Innovations in Infection Prevention" 2021 award was presented to PhoneSoap acknowledging their exceptional organization who is making a difference in the Infection Prevention community, with their innovative products, services, and technologies.

The award was accepted by Wes LaPorte, CEO of PhoneSoap. "PhoneSoap's mission has always been to limit the spread of infectious diseases through science and technology. We are honored to accept the Innovations in Infection Prevention award of 2021 from the C Diff Foundation given their very important endeavor to bring awareness, education, and advocacy globally," stated LaPorte.

According to the 2017 Update (published February 2018) of the Clinical Practice Guidelines for C. difficile Infection by the Infectious Diseases Society of America (IDSA) and Society or Healthcare Epidemiology of America (SHEA), CDI remains a significant medical problem in hospitals, in long-term care facilities and in the community. C. difficile is one of the most common causes of health care- associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the U.S. and is associated with approximately 20,000 deaths annually. (Guh, 2020, New England Journal of Medicine).

Based on internal estimates, the recurrence rate of two of the three antibiotics currently used to treat CDI is between 20% and 40% among approximately 150,000 patients treated. We believe the annual incidence of CDI in the U.S. approaches 600,000 infections and has a mortality rate of approximately 9.3%.

The C Diff Foundation expresses their gratitude to all the Sponsors and Keynote speakers for their generous support of the 9th Annual International C. diff. Conference and Health EXPO. Together we deliver superior educational up-to-date data, advance the healthcare professional knowledge and understanding of the topics discussed, and serve as the leading organization educating and advocating for C. difficile infection prevention, treatments, clinical trial, diagnostics, support, and environmental safety worldwide. We are grateful to be the leading resource for patients, families, caregivers, and healthcare professionals.

Many US Governors have signed a state proclamation proclaiming November 2021 as Clostridioides difficile (C. difficile, C. diff.) Infection Awareness Month.

"Our shared goal is to witness a significant increase in C. difficile awareness, with a noted reduction in C. difficile infections worldwide by the year 2025. We would also like to thank Seres Therapeutics, Rebiotix, a Ferring Company, and Ferring Pharmaceuticals for their efforts and support with this endeavor," stated Nancy C. Caralla, Executive Director of the C Diff Foundation.

About C Diff Foundation:

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient, caregiver, and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide.

For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation

#cdiff2021 #cdiffawarenessmonth

C Diff Foundation(TM) is a trademark of C Diff Foundation, established 2012 in the U.S.

Related link: https://cdifffoundation.org/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles, NonProfit and Charities, Regional Events

C Diff Foundation Hosts 4th Annual Global C. diff. Awareness 2K Virtual Walks

TEANECK, N.J. -- C Diff Foundation announced today that registration is open for the 4th Annual Global C. diff. Awareness 2K Virtual Walks. This year's annual events will take place online and will be recorded at the Morris A. Votee Park, Teaneck, NJ, Charlestown Township Park, Phoenixville, PA, Sims Park, New Port Richey, FL on Saturday, September 12, 2020 from 8 a.m. - 12 p.m. ET. There will also be a superhero virtual show for super kids. Dr. Martha Clokie, Ph.D. will be leading the walk which will be recorded in Leicester, UK on Friday, September 11, 2020.

Registration is $20 per walker and complimentary for children 10 years of age and under. Learn more: https://cdifffoundation.org/cdiffwalk2020/

All registered awareness walkers will receive a t-shirt, giveaways, and educational material. Proceeds from the events will benefit the C Diff Foundation's mission educating and advocating for C. difficile infection prevention, treatments, clinical trials, and environmental safety worldwide. During these unprecedented times, caused by the COVID-19 pandemic, the C Diff Foundation effectively adapts to overcome the many obstacles developing from this global virus.

C. diff. infections are one of the leading healthcare-associated infections facing local communities worldwide. According to the Centers for Disease Control and Prevention (CDC), a Clostridioides difficile infection (C. diff., C. difficile), (formally known as Clostridium difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone."

Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

"Every day the C Diff Foundation members work to educate and advocate for C. difficile infection prevention, treatments, clinical trials, and environmental safety while providing support worldwide," says Nancy Caralla, Founding President, and Executive Director of the C Diff Foundation. "Our dedication to the cause is making a difference as we share a common goal with government agencies and health care organizations witnessing a decrease in newly diagnosed C.diff. infections and saving lives. Our dedicated volunteering members, around the globe, are focused on improving the lives of individuals and families who are impacted by C. diff. infections."

We sincerely thank Vedanta Biosciences, Inc. for being the Diamond Sponsor of the 4th Annual Global C. diff. Awareness 2K Virtual Walks. Vedanta Biosciences, Inc. is dedicated to finding treatments for patients with serious infections and immune diseases. Vedanta develops medicines made of consortia of bacterial strains which are selected to effect robust and durable changes in a patient's gut microbiota.

In contrast to fecal transplants or administration of fecal fractions, Vedanta's medicines are pure, uniform compositions of bacteria manufactured from clonal cell banks, bypassing the need to rely on direct sourcing of fecal donor material of inconsistent composition. Vedanta is currently enrolling patients with recurrent C. difficile infections (CDI) in its CONSORTIUM study to evaluate VE303, an investigational treatment for CDI.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) supports public health through educating and advocating for C. difficile infection prevention, treatments, clinical trials, and environmental safety worldwide. For more information, or to find out how you can be a host of a Global C.diff. Awareness 2K Walk, visit http://www.cdifffoundation.org.

Follow C Diff Foundation on Twitter: @cdiffFoundation #CdiffWalk2020

Media Contact:
Kathy Bischoff, Global Walk Committee
kathy@cdifffoundation.org

*IMAGE LINK FOR MEDIA: https://www.Send2Press.com/300dpi/20-0819s2p-Cdiff-WALK-300dpi.jpg

Related link: https://cdifffoundation.org/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles, NonProfit and Charities

C.diff. International Conference and Health EXPO Will Deliver Up-to-date Clostridioides difficile Data + More Nov. 6-7 In St. Louis

ST. LOUIS, Mo. -- The C Diff Foundation is honored to welcome 30+ international leading topic experts from hospitals, pharma, biotech, academia, and Government agencies to deliver and discuss critical information on global healthcare-associated issues.

To learn more about this extraordinary conference, agenda and guest speakers: https://cdifffoundation.org/2019-guest-speakers/

Clinical professionals will gather for two days to present up-to-date data to expand on the existing knowledge and raise awareness of the urgency focused on, but not limited to, Clostridioides difficile (formally known as Clostridium difficile) infection (CDI) Prevention, Treatments, Research, Diagnostics, Clinical trials, and Environmental Safety.

There will also be presentations exclusively concentrated on Infection prevention, Fecal microbiota restoration and transplants for adults, a Panel of C. diff. infection Survivors; a patient's perspective, Microbiome research, Scientific posters and poster presentations, Antibiotic stewardship, Antimicrobial resistance, and a Healthcare EXPO component.

All attendees will have the highest levels of peer networking and learning opportunity at the Conference and Health EXPO. The conference program builds in time for face-to-face interaction between attending executives, corporate representatives and industry experts exhibiting.

C Diff Foundation expresses their gratitude to Pfizer for being the conference Diamond Sponsor. Pfizer is appreciated for their continued support and partnering with the C Diff Foundation in promoting C. diff. Awareness worldwide.

Attendee Linda Davis, RN, Patient Triage Specialist, said about the 2018 conference, "It's an excellent opportunity to have the ability to network with fellow-healthcare professionals from around the world. Each conference I have attended presents the opportunity to acquire knowledge with like-minded professionals striving to make a difference in the health care community. Attendees obtain the most innovative cutting-edge research and developments fighting today's complex world of healthcare-associated infections."

According to the Centers for Disease Control and Prevention (CDC), Clostridioides difficile infection (aka C.diff., C. difficile, CDI, CDAD) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile infections cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, and environmental safety worldwide. Listen to "C.diff. Spores and More" Tuesdays at 1 p.m. ET (www.cdiffradio.com), sponsored by Rebiotix, a Ferring Pharmaceuticals company, providing leading up-to-date information on topics that are aligned and connect with their organization's mission and more.

Learn more: https://cdifffoundation.org/

Follow C Diff Foundation on LinkedIn, Facebook, and Instagram. Twitter @cdiffFoundation #Cdiff2019

Media Contact:
Angelo Ortiz
C Diff Foundation
angelo.ortiz@cdifffoundation.org
Office: (727) 205-3922

Related link:

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles, NonProfit and Charities

World Renowned C Diff Foundation Announces First Ever Appointment of Paul Feuerstadt, M.D. as Director of Medical Education

NEW PORT RICHEY, Fla. -- C Diff Foundation, a one hundred percent volunteer, world renowned 501(c)(3) not-for-profit organization, has appointed nationally renowned Gastroenterologist, Dr. Paul Feuerstadt as its first Director of Medical Education.

Dr. Feuerstadt said, "It is my honor to accept this position. I have been involved with the C Diff Foundation over the last 4.5 years and I look forward to assisting in the continued growth of the organization and ensuring that forward progress, awareness and education increases under my tenure. I look forward to working with the board and volunteers to increase awareness and funding across the country and around the world to highlight this disease through in person events, social media, and in the press."

Dr. Feuerstadt has spent his career refining his practice and expertise in C. difficile. He is dedicated to educating the public through his work with this organization.

Additionally, he plans to offer free patient and provider education through the launch of his new educational website, https://www.everythingcdifficile.com/. The goal of the site is to provide education through short videos with relevant clinical information for educational purposes. The site provides concise 3-5 minute lectures covering core topics, recent publications and major conferences about C. difficile infection to educate both patients and providers.

Nancy C. Caralla, Founding President, C Diff Foundation, commented: "Dr. Feuerstadt is a pre-eminent doctor in this space. His dedication and donation of his time and energy to this worthy cause has helped so many patients to date. We look forward to his enhanced leadership and knowledge as the organization grows and strengthens through our advocacy in the C.diff. community. Dr. Feuerstadt's new role as Director of Medical Education will provide an additional avenue of support to patients, families, and caregivers through his educational media available on EverythingCdifficile.com. We are grateful for Dr. Feuerstadt's time and dedication as we continue fighting this debilitating disease worldwide."

About C Diff Foundation:

The C Diff Foundation's mission is dedicated to reaching out to communities from villages to cities, to medical practitioners, medical students, C. diff. survivors, caregivers, and the patients combating a C. difficile infection (CDI) while providing the general public important information on prevention, treatments available, clinical trials in progress, and EPA registered products available for environmental safety.

The C Diff Foundation continues moving forward setting up outreach centers and building positive networks with the C Diff Foundation Volunteer Health Advocates aiding in "Raising C.diff. Awareness" worldwide.

Learn more: https://cdifffoundation.org/

About Dr. Paul Feuerstadt:

His areas of interest Clostridioides difficile infection and ischemic diseases of the gut and in these areas he has presented his research extensively, authored and co-authored many manuscripts, textbook chapters and online modules. Another passion of Dr. Feuerstadt's is teaching, frequently giving lectures locally, regionally and nationally. He holds a clinical appointment as an Assistant Clinical Professor of Medicine at the Yale University School of Medicine and is a full time attending physician at the Gastroenterology Center of Connecticut seeing patients with a broad spectrum of clinical gastroenterological diseases.

Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan for medical school and completed his residency in internal medicine at New York Presbyterian Hospital/Weill Cornell. His clinical fellowship training was completed at Montefiore Medical Center in the Bronx, New York.

About C.difficile:

It is the most common Healthcare-associated infection affecting an estimated 450,000 people annually in the United States alone with ~28,000 deaths from complications of this infection. This infection accounts for ~16% of all healthcare associated infections.

In the USA: Nearly half a million Americans suffer from Clostridioides difficile (C. diff.) infections in a single year according to a study released February 25, 2015 by the Centers for Disease Control and Prevention CDC).

**Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. Of those, about 15,000 deaths were estimated to be directly attributable to C. difficile infections (CDI), making C. difficile a very important cause of infectious disease death in the United States alone. More than 80 percent of the deaths associated with C. difficile occurred among Americans aged 65 years or older. C. difficile causes an inflammation of the colon and deadly diarrhea.

Related link:

This news story was published by the Neotrope® News Network - all rights reserved.

Free News Articles, General Editorial, Hospitals and Nursing, NonProfit and Charities, Regional Events

Inaugural Global C. diff. Walk to raise awareness on importance of Clostridium difficile infection prevention and provide resources

NEW PORT RICHEY, Fla. -- Presented by the C Diff Foundation, the 1st Annual Global C.diff. Awareness 2K Walk will take place on Saturday, November 4 at Frances Park, New Port Richey, Florida. This event will include refreshments, hydration stations, and resourceful educational material and displays.

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection (C. difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

The Global C. diff. Walk seeks to raise awareness of Clostridium difficile (C. diff.) infection prevention and provide educational material while introducing the community to the resources available. C.diff. infections are one of the leading health issues facing local communities.

"Every day the C Diff Foundation works to educate and advocate for C. difficile infection prevention, treatments, environmental safety and support worldwide to save lives. Our dedicated volunteering members and patient advocates work to improve the lives of individuals and families that are impacted by a C.diff. infection," says Nancy Caralla, Board President of the C Diff Foundation.

We sincerely thank the following Sponsor for their continued support and for joining the C Diff Foundation in promoting C. diff. Awareness worldwide: Diamond: Seres Therapeutics.

Event Details:
Saturday, November 4, 2017. Registration and Check-in takes place at 8 a.m. Walk and Program begins at 9 a.m. at Frances Park, 5580 Frances Avenue, New Port Richey, Florida 34653.

Registration: https://cdifffoundation.org/.

Walkers can register individually ($5 per person) or as a team ($15 per team) and can recruit sponsors.

All funds raised will support the work of the C Diff Foundation that provide villages to cities with C. difficile infection education, advocacy, and support worldwide.

For additional information about the walk, email info@cdifffoundation.org or call (919)-201-1512.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide.

Follow C Diff Foundation on Twitter
@cdiffFoundation
#Cdiff2017

*IMAGE: Send2Press.com/300dpi/17-1003s2p-cdiff2k-flier-300dpi.jpg

Related link:

This news story was published by the Neotrope® News Network - all rights reserved.

Free News Articles, NonProfit and Charities

C Diff Foundation’s 4th Annual C. diff. Awareness Global Campaign Begins on Nov. 1, 2016

NEW PORT RICHEY, Fla. -- C Diff Foundation(R) a leading non-profit patient advocacy organization, Global healthcare information system, today announced the scheduled events and launching of the 4th annual November C. diff. Awareness global campaign, the first month long awareness campaign of its kind in the healthcare industry. November 1st is dedicated to all C. diff. Survivors worldwide.

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection (C. difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

"The C Diff Foundation members and volunteer patient advocates are dedicated in Raising C. diff. Awareness from villages to cities by sharing life-saving information," stated Nancy C. Caralla, C Diff Foundation's Foundress, and Executive Director.

November 4th attend the Tampa Bay Community "Raising C. diff. Awareness" event. Healthcare professionals deliver presentations beginning at 5:30 p.m. Spartan Manor, New Port Richey, FL. Tickets are $25, available online www.cdifffoundation.org or call 1-844-367-2343. We express our gratitude to our Corporate Sponsor: Xenex (www.xenex.com) and this activity is being supported by an independent patient advocacy grant from Merck & Co., Inc.

FREE 4 hour webinar on November 11, with 8 international healthcare professionals provided by the Global C.difficile Congress. "The goal is to broaden existing knowledge focused on C. difficile infection prevention, treatments, research, and environmental safety worldwide," says Caralla.

Register online http://globalcdifficilecongress.org/.

C. diff. community corporations around the globe are partnering to raise awareness and witness a shared goal in driving down newly diagnosed C. difficile infections and saving lives.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) non-profit, Founded in 2012 by Nancy C. Caralla, a nurse who was diagnosed and treated for Clostridium difficile (C. diff.) infections. Through her own journeys and the loss of her father to C. difficile infection involvement, Nancy recognized the need for greater awareness through education, about research being conducted by the government, industry, and academia and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating, life-threatening infection.

About The C diff Foundation Foundress, Executive Director:

Nancy C Caralla, hosts "C. diff. Spores and More" Global Broadcasting Network, and shares in a team focus on educating, and advocating for C. diff. infection prevention, treatments, and environmental safety -- and more -- worldwide.

Information: https://www.cdifffoundation.org/.

Twitter: @cdiffFoundation #Nov4Cdiff

IMAGE for media: Send2Press.com/mediaboom/16-1020s2p-cdiff-300dpi.jpg

This news story was published by the Neotrope® News Network - all rights reserved.